Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Bioline RX Ltd Sponsored ADR ( (BLRX) ) is now available.
BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing a pipeline led by GLIX1, a first-in-class DNA damage response modulator for glioblastoma and other solid tumors, alongside its approved stem cell mobilization therapy APHEXDA for multiple myeloma. The company collaborates with Hemispherian AS on GLIX1 and with academic partners on ongoing trials, while APHEXDA is commercialized by Ayrmid outside Asia and Gloria Biosciences in Asia.
On March 26, 2026, BioLineRx announced it has initiated a first-in-human Phase 1/2a clinical trial of GLIX1 for recurrent and progressive glioblastoma and other high-grade gliomas, marking a key operational milestone in the first quarter of 2026. The oral TET2-activating molecule, which has shown strong anti-tumor activity, robust blood-brain barrier penetration and a favorable preclinical safety profile, will be studied at leading U.S. neuro-oncology centers, with up to 30 patients in Phase 1 and expansion cohorts in Phase 2a aimed at defining dose, safety and preliminary efficacy to underpin a broader development strategy.
The study is being led by prominent glioblastoma investigators at NYU Langone Health, Northwestern University and Moffitt Cancer Center, underscoring GLIX1’s scientific profile and BioLineRx’s effort to position itself at the forefront of innovative brain cancer treatments. For stakeholders, the trial launch signals a strategic push into high-need neuro-oncology indications, with initial clinical data expected in the first half of 2027 that could materially influence the company’s pipeline value and competitive standing in glioblastoma therapeutics.
The most recent analyst rating on (BLRX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Bioline RX Ltd Sponsored ADR stock, see the BLRX Stock Forecast page.
Spark’s Take on BLRX Stock
According to Spark, TipRanks’ AI Analyst, BLRX is a Neutral.
BioLine RX Ltd’s overall stock score reflects significant revenue growth and strategic initiatives, but is weighed down by ongoing profitability challenges and a bearish technical outlook. The company’s strong cash position and potential in innovative treatments are promising, yet current revenue generation and market penetration remain hurdles.
To see Spark’s full report on BLRX stock, click here.
More about Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on oncology and rare diseases, listed on NASDAQ and TASE under the ticker BLRX. Its lead development asset is GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other solid tumors, and it also markets APHEXDA for stem cell mobilization in multiple myeloma through commercialization partners while retaining rights to develop motixafortide in solid tumors.
Average Trading Volume: 16,130
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.89M
Learn more about BLRX stock on TipRanks’ Stock Analysis page.